qls1128
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jul 3, 2022 (NCT05458076)
Timeline
Indications
Studied for
Mechanism of action
- Replicase polyprotein 1aINHIBITOR
Replicase polyprotein 1a inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05758519 | Phase 3 | Mar 7, 2023 | Qilu Pharmaceutical Co., Ltd. |
| NCT05689203 | Phase 2 | Dec 30, 2022 | Qilu Pharmaceutical Co., Ltd. |
| NCT05458076 | Phase 1 | Jul 3, 2022 | Qilu Pharmaceutical Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 3 | 2022 |
1 organizations
Page 1 / 1